Bill Gates Believes India Can Provide COVID-19 Vaccines For The Whole World

Harin - Jul 20, 2020

Bill Gates is confident that Indian pharmaceutical companies can produce enough COVID-19 vaccines for the entire world, not just India.

The Indian pharmaceutical industry is racing to produce COVID-19 vaccines. And it has earned support from Bill Gates, the Microsoft co-founder, and philanthropist.

Bill Gates is confident that Indian pharmaceutical companies can produce enough COVID-19 vaccines for the entire world.

Gates thought highly of the capacity of the pharma industry of the country. For a long time, India has become the world’s vaccine manufacturing hub. The country has manufactured more vaccines than the rest of the world.

India has done a lot of extremely important things. Its pharma industry is working on the coronavirus vaccine using other great capacities used for other diseases. Speaking in the COVID-19: India’s War Against The Virus, Gates added that India had also been facing a huge health crisis because of the country’s size and population density.

He also praised the Serum Institute for its role as the world’s largest vaccine supplier and Bharat Biotech and Bio E for their COVID-19 vaccine developing efforts.

Serum India will be in charge of manufacturing the COVID-19 vaccine currently on human trials at Oxford University, the UK. The company’s goal is to produce four to five million doses of vaccines each month in the first six months. After that, they might scale up the production to 10 million doses monthly. By September-October, Serum Institute is planning to produce 20 to 40 million doses. By doing this, the product will be available in other countries as well.

Meanwhile, COVAXIN, the first indigenous COVID-19 vaccine of India, developed by Bharat Biotech has received approval to carry out human clinical trials.

The Drug Controller General of India has allowed Bharat Biotech to conduct Phase I and II of human trials. As per the vaccine maker, its clinical trials of the vaccine will begin in July 2020. The company said that the vaccine’s development was in collaboration with the National Institute of Virology and Indian Council of Medical Research.